Cargando…
High sensitivity versus low level of vancomycin needs to be concern for another alternative anti-Staphylococcus aureus as the first- line antibiotic
Background and aim: Vancomycin has been the first-line therapy for MRSA infection disease for many years. According to standard guidelines, the therapeutic vancomycin trough concentration should be above 10 mg/L and optimally between 15-20 mg/L. The aim of this study was to evaluate vancomycin troug...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mattioli 1885
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233789/ https://www.ncbi.nlm.nih.gov/pubmed/31910175 http://dx.doi.org/10.23750/abm.v90i4.7646 |
_version_ | 1783535614655725568 |
---|---|
author | Talaie, Haleh Mousavizadeh, Atieh Emami, Habib Gachkar, Latif Barari, Behjat Alijanzadeh, Mohammad Hossein |
author_facet | Talaie, Haleh Mousavizadeh, Atieh Emami, Habib Gachkar, Latif Barari, Behjat Alijanzadeh, Mohammad Hossein |
author_sort | Talaie, Haleh |
collection | PubMed |
description | Background and aim: Vancomycin has been the first-line therapy for MRSA infection disease for many years. According to standard guidelines, the therapeutic vancomycin trough concentration should be above 10 mg/L and optimally between 15-20 mg/L. The aim of this study was to evaluate vancomycin trough level concentration in patients infected with MRSA.Methods: This cross- sectional study included a sample of 170 patients admitted to the ICU of Loghman hospital. We used a standard questionnaire, then applied appropriate statistical tests. All collected data had been analyzed and interpreted by IBM SPSS Statistics 19.0.Results: Among this study population, 71.8% was male. Just 20.8% of the patients can reach the therapeutic level trough even after changing the dose. It should be noted that a significant percentage of toxicity was observed after increasing the dose. Conclusions: Even though high sensitivity against vancomycin disc has been seen in antibiogram tests, sufficient efficiency has not been distinguished, in the sense that, just a few patients by low trough level concentration, reached to therapeutic level after the dose change. Based on some sources, because of the side effects and limited safe range of vancomycin, we should consider a new approach to the alternative antibiotics. (www.actabiomedica.it) |
format | Online Article Text |
id | pubmed-7233789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Mattioli 1885 |
record_format | MEDLINE/PubMed |
spelling | pubmed-72337892020-05-19 High sensitivity versus low level of vancomycin needs to be concern for another alternative anti-Staphylococcus aureus as the first- line antibiotic Talaie, Haleh Mousavizadeh, Atieh Emami, Habib Gachkar, Latif Barari, Behjat Alijanzadeh, Mohammad Hossein Acta Biomed Original Article Background and aim: Vancomycin has been the first-line therapy for MRSA infection disease for many years. According to standard guidelines, the therapeutic vancomycin trough concentration should be above 10 mg/L and optimally between 15-20 mg/L. The aim of this study was to evaluate vancomycin trough level concentration in patients infected with MRSA.Methods: This cross- sectional study included a sample of 170 patients admitted to the ICU of Loghman hospital. We used a standard questionnaire, then applied appropriate statistical tests. All collected data had been analyzed and interpreted by IBM SPSS Statistics 19.0.Results: Among this study population, 71.8% was male. Just 20.8% of the patients can reach the therapeutic level trough even after changing the dose. It should be noted that a significant percentage of toxicity was observed after increasing the dose. Conclusions: Even though high sensitivity against vancomycin disc has been seen in antibiogram tests, sufficient efficiency has not been distinguished, in the sense that, just a few patients by low trough level concentration, reached to therapeutic level after the dose change. Based on some sources, because of the side effects and limited safe range of vancomycin, we should consider a new approach to the alternative antibiotics. (www.actabiomedica.it) Mattioli 1885 2019 2019-12-23 /pmc/articles/PMC7233789/ /pubmed/31910175 http://dx.doi.org/10.23750/abm.v90i4.7646 Text en Copyright: © 2019 ACTA BIO MEDICA SOCIETY OF MEDICINE AND NATURAL SCIENCES OF PARMA http://creativecommons.org/licenses/by-nc-sa/4.0 This work is licensed under a Creative Commons Attribution 4.0 International License |
spellingShingle | Original Article Talaie, Haleh Mousavizadeh, Atieh Emami, Habib Gachkar, Latif Barari, Behjat Alijanzadeh, Mohammad Hossein High sensitivity versus low level of vancomycin needs to be concern for another alternative anti-Staphylococcus aureus as the first- line antibiotic |
title | High sensitivity versus low level of vancomycin needs to be concern for another alternative anti-Staphylococcus aureus as the first- line antibiotic |
title_full | High sensitivity versus low level of vancomycin needs to be concern for another alternative anti-Staphylococcus aureus as the first- line antibiotic |
title_fullStr | High sensitivity versus low level of vancomycin needs to be concern for another alternative anti-Staphylococcus aureus as the first- line antibiotic |
title_full_unstemmed | High sensitivity versus low level of vancomycin needs to be concern for another alternative anti-Staphylococcus aureus as the first- line antibiotic |
title_short | High sensitivity versus low level of vancomycin needs to be concern for another alternative anti-Staphylococcus aureus as the first- line antibiotic |
title_sort | high sensitivity versus low level of vancomycin needs to be concern for another alternative anti-staphylococcus aureus as the first- line antibiotic |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233789/ https://www.ncbi.nlm.nih.gov/pubmed/31910175 http://dx.doi.org/10.23750/abm.v90i4.7646 |
work_keys_str_mv | AT talaiehaleh highsensitivityversuslowlevelofvancomycinneedstobeconcernforanotheralternativeantistaphylococcusaureusasthefirstlineantibiotic AT mousavizadehatieh highsensitivityversuslowlevelofvancomycinneedstobeconcernforanotheralternativeantistaphylococcusaureusasthefirstlineantibiotic AT emamihabib highsensitivityversuslowlevelofvancomycinneedstobeconcernforanotheralternativeantistaphylococcusaureusasthefirstlineantibiotic AT gachkarlatif highsensitivityversuslowlevelofvancomycinneedstobeconcernforanotheralternativeantistaphylococcusaureusasthefirstlineantibiotic AT bararibehjat highsensitivityversuslowlevelofvancomycinneedstobeconcernforanotheralternativeantistaphylococcusaureusasthefirstlineantibiotic AT alijanzadehmohammadhossein highsensitivityversuslowlevelofvancomycinneedstobeconcernforanotheralternativeantistaphylococcusaureusasthefirstlineantibiotic |